Top Suppliers:I want be here


  • DC Chemicals Limited
  • China
  • Product Name: Razoxane
  • Price: $Inquiry/100mg $Inquiry/250mg $Inquiry/500mg
  • Purity: 98.0%
  • Stocking Period: 3 Day
  • Contact: Tony Cao

21416-67-1

21416-67-1 structure
21416-67-1 structure
  • Name: Razoxane
  • Chemical Name: 4,4'-(Propane-1,2-diyl)bis(piperazine-2,6-dione)
  • CAS Number: 21416-67-1
  • Molecular Formula: C11H16N4O4
  • Molecular Weight: 268.26900
  • Catalog: Biochemical Inhibitor Immune inhibitor
  • Create Date: 2018-06-20 18:11:28
  • Modify Date: 2024-01-07 14:47:17
  • Razoxane (ICRF 159) is an antiangiogenic topoisomerase II inhibitor, can be used for the research of renal cell carcinoma (RCC)[1].

Name 4,4'-(Propane-1,2-diyl)bis(piperazine-2,6-dione)
Synonyms 4,4'-propylenebis(piperazine-2,6-dione)
4,4'-Propane-1,2-diyldipiperazine-2,6-dione
4,4'-(1-Methylethylene)bis(2,6-piperazinedione)
dl-1,2-bis(3,5-dioxopiperazin-1-yl)-propane
Propyliminum
RAZOXANUM
1,2-bis(3,5-dioxopiperazin-1-yl)-propane
(+)-1,2-bis(3,5-dioxopiperazinyl)propane
(+)-1,2-bis(3,5-dioxopiperazinyl-1-yl)propane
Razoxane
Description Razoxane (ICRF 159) is an antiangiogenic topoisomerase II inhibitor, can be used for the research of renal cell carcinoma (RCC)[1].
Related Catalog
Target

Topoisomerase II

In Vitro Razoxane (30 mg/kg; i.p.) exhibits antimetastatic effects in a rat osteosarcoma model.
In Vivo Early treatment with Razoxane (30 mg/kg i.p. from day -2 to +14) shows a greater inhibition of pulmonary metastases than later treatment (30 mg/kg i.p. from day +14 to +28 after transplantation)[2]. Animal Model: Sprague-Dawley rats[2] Dosage: 30 mg/kg or 10 mg/kg per day Administration: Intraperitoneally (i.p.) from 2 days before to 14 days after tumor transplantation Result: Resulted in a dose-dependent prolongation of median survival time (83 or 48 days respectively, versus 38 days for the control group), but showed no influence on the growth of the primary tumor.
References

[1]. J P Braybrooke, et al. A phase II study of Razoxane, an antiangiogenic topoisomerase II inhibitor, in renal cell cancer with assessment of potential surrogate markers of angiogenesis. Clin Cancer Res.2000; 6(12):4697-704.

[2]. F Wingen, et al. Antimetastatic effects of Razoxane in a rat osteosarcoma model. Clin Exp Metastasis.Jan-Mar 1987; 5(1):9-16.

Density 1.333g/cm3
Boiling Point 531.5ºC at 760mmHg
Melting Point 193ºC
Molecular Formula C11H16N4O4
Molecular Weight 268.26900
Flash Point 275.3ºC
Exact Mass 268.11700
PSA 98.82000
Vapour Pressure 1.33E-13mmHg at 25°C
Index of Refraction 1.534
Storage condition room temp
Water Solubility DMSO: soluble40mg/mL

CHEMICAL IDENTIFICATION

RTECS NUMBER :
TL6389900
CHEMICAL NAME :
2,6-Piperazinedione, 4,4'-propylenedi-
CAS REGISTRY NUMBER :
21416-67-1
BEILSTEIN REFERENCE NO. :
0821182
LAST UPDATED :
199612
DATA ITEMS CITED :
15
MOLECULAR FORMULA :
C11-H16-N4-O4
MOLECULAR WEIGHT :
268.31
WISWESSER LINE NOTATION :
T6VMV ENTJ EY1&1- ET6VMV ENTJ

HEALTH HAZARD DATA

ACUTE TOXICITY DATA

TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
3650 mg/kg/2Y-I
TOXIC EFFECTS :
Kidney, Ureter, Bladder - hematuria Blood - aplastic anemia
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
600 mg/kg/34W-I
TOXIC EFFECTS :
Blood - leukopenia
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Unreported
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
6467 mg/kg/6Y-I
TOXIC EFFECTS :
Blood - normocytic anemia Blood - thrombocytopenia
TYPE OF TEST :
LD50 - Lethal dose, 50 percent kill
ROUTE OF EXPOSURE :
Intraperitoneal
SPECIES OBSERVED :
Rodent - mouse
DOSE/DURATION :
500 mg/kg
TOXIC EFFECTS :
Tumorigenic - active as anti-cancer agent
TYPE OF TEST :
TDLo - Lowest published toxic dose
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
693 mg/kg/77W-I
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Blood - leukemia
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
4650 mg/kg/2Y-C
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Blood - leukemia
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - man
DOSE/DURATION :
2693 mg/kg/3Y-C
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Skin and Appendages - tumors
TYPE OF TEST :
TD - Toxic dose (other than lowest)
ROUTE OF EXPOSURE :
Oral
SPECIES OBSERVED :
Human - woman
DOSE/DURATION :
3650 mg/kg/2Y-I
TOXIC EFFECTS :
Tumorigenic - Carcinogenic by RTECS criteria Blood - leukemia
TYPE OF TEST :
Micronucleus test

MUTATION DATA

TEST SYSTEM :
Rodent - hamster
DOSE/DURATION :
100 mg/kg
REFERENCE :
BJCAAI British Journal of Cancer. (Macmillan Press Ltd., Houndmills, Basingstoke, Hants. RG21 2XS, UK) V.1- 1947- Volume(issue)/page/year: 52,725,1985
RIDADR NONH for all modes of transport
RTECS TL6389900